Status:
WITHDRAWN
VX-770 for the Treatment of Chronic Bronchitis
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Chronic Bronchitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This research study will test how well a new drug affects bronchiectasis or chronic bronchitis. The new drug, Ivacaftor (KALYDECO), is a drug that has recently been approved by the U.S. Food and Drug ...
Detailed Description
The study is an open label study of orally-administered ivacaftor in subjects with chronic bronchitis and/or bronchiectasis. Subjects will be administered the study drug ivacaftor 150 mg twice daily (...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or Female age 18 years
- A Clinical diagnosis of Bronchiectasis and/or Chronic Bronchitis in the investigators opinion
- Exhibit symptoms of chronic bronchitis as defined by the Medical Research Council
- FEV1 percent predicted greater than 40 percent Post Bronchodilator
- Clinically stable in the last 4 weeks with no evidence of exacerbation
- Weight of 40 kg to120 kg
- Willingness to use at least one form of acceptable birth control including abstinence, condom with spermicide, or hormonal contraceptives
- Willing to monitor blood glucose if known history of diabetes mellitus requiring insulin or medical therapy
- Element of CFTR Dysfunction, as defined by Sweat Chloride
- Exclusion
- Daytime use of Oxygen Therapy
- Documented history of drug abuse within the last year
- Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease within 28 days before receiving the first dose of study drug.
- Cirrhosis or elevated liver transaminases \> 3X ULN
- GFR \< 50 estimated by Cockroft-Gault
- Any illness or abnormal lab finding that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject.
- Pregnant or Breastfeeding
- Subjects taking any inhibitors or inducers of CYP3A4, including certain herbal medications and grapefruit juice. (Excluded medications and foods including the drugs and foods are provided in the appendix document)
- Uncontrolled Diabetes
- Clinically significant arrhythmias or conduction abnormalities that in the opinion of the investigator that affect patient safety
Exclusion
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03251911
Start Date
January 1 2020
End Date
February 1 2022
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233